Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
O'Connell RJ, Excler JL, Polonis VR, Ratto-Kim S, Cox J, Jagodzinski LL, Liu M, Wieczorek L, McNeil JG, El-Habib R, Michael NL, Gilliam BL, Paris R, VanCott TC, Tomaras GD, Birx DL, Robb ML, Kim JH. O'Connell RJ, et al. Among authors: tomaras gd. J Infect Dis. 2016 Jun 15;213(12):1946-54. doi: 10.1093/infdis/jiw059. Epub 2016 Feb 11. J Infect Dis. 2016. PMID: 26908741 Free PMC article. Clinical Trial.
Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.
Sufka SA, Ferrari G, Gryszowka VE, Wrin T, Fiscus SA, Tomaras GD, Staats HF, Patel DD, Sempowski GD, Hellmann NS, Weinhold KJ, Hicks CB. Sufka SA, et al. Among authors: tomaras gd. J Infect Dis. 2003 Apr 1;187(7):1027-37. doi: 10.1086/368359. Epub 2003 Mar 13. J Infect Dis. 2003. PMID: 12660916 Clinical Trial.
Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.
Johnson DC, McFarland EJ, Muresan P, Fenton T, McNamara J, Read JS, Hawkins E, Bouquin PL, Estep SG, Tomaras GD, Vincent CA, Rathore M, Melvin AJ, Gurunathan S, Lambert J. Johnson DC, et al. Among authors: tomaras gd. J Infect Dis. 2005 Dec 15;192(12):2129-33. doi: 10.1086/498163. Epub 2005 Nov 9. J Infect Dis. 2005. PMID: 16288378 Clinical Trial.
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.
Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, Metch BJ, Hansen M, Allen M, Cao H, Montefiori DC, Tomaras GD, Gurunathan S, Eastman DJ, do Lago RF, Jean S, Lama JR, Lawrence DN, Wright PF; 026 Protocol Team and the NIAID HIV Vaccine Trials Network. Cleghorn F, et al. Among authors: tomaras gd. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):222-30. doi: 10.1097/QAI.0b013e318149297d. J Acquir Immune Defic Syndr. 2007. PMID: 17693888 Clinical Trial.
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination.
Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, Overman RG, Ochsenbauer C, Edmonds TG, Kappes JC, Cunningham CK, Denny TN, Weinhold KJ, Ferrari G, Haynes BF, Koup RA, Graham BS, Roederer M, Tomaras GD. Freel SA, et al. Among authors: tomaras gd. J Virol. 2010 May;84(10):4998-5006. doi: 10.1128/JVI.00138-10. Epub 2010 Mar 3. J Virol. 2010. PMID: 20200250 Free PMC article.
Is developing an HIV-1 vaccine possible?
Haynes BF, Liao HX, Tomaras GD. Haynes BF, et al. Among authors: tomaras gd. Curr Opin HIV AIDS. 2010 Sep;5(5):362-7. doi: 10.1097/COH.0b013e32833d2e90. Curr Opin HIV AIDS. 2010. PMID: 20978375 Free PMC article. Review.
Strategies for eliciting HIV-1 inhibitory antibodies.
Tomaras GD, Haynes BF. Tomaras GD, et al. Curr Opin HIV AIDS. 2010 Sep;5(5):421-7. doi: 10.1097/COH.0b013e32833d2d45. Curr Opin HIV AIDS. 2010. PMID: 20978384 Free PMC article. Review.
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Goepfert PA, et al. Among authors: tomaras gd. J Infect Dis. 2011 Mar 1;203(5):610-9. doi: 10.1093/infdis/jiq105. Epub 2011 Jan 31. J Infect Dis. 2011. PMID: 21282192 Free PMC article. Clinical Trial.
390 results